Patents by Inventor Elazar Rabbani

Elazar Rabbani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11181528
    Abstract: Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 23, 2021
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, Joshua Rabbani, Praveen Pande
  • Patent number: 11173195
    Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and transforming growth factor beta, (TGF-?).
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: November 16, 2021
    Assignee: Enzo Biochem, Inc.
    Inventors: Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
  • Publication number: 20210301357
    Abstract: The invention provides comprehensive and comparative flow cytometry-based methods for characterizing the state of a biological system by determining cell phenotypes and associated gene expression profiles.
    Type: Application
    Filed: May 4, 2021
    Publication date: September 30, 2021
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan, Andrew Stewart L'Huillier
  • Publication number: 20210290600
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: March 10, 2021
    Publication date: September 23, 2021
    Applicant: Enzo Biochem, Inc.
    Inventor: Elazar Rabbani
  • Publication number: 20210290567
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: March 10, 2021
    Publication date: September 23, 2021
    Applicant: Enzo Biochem, Inc.
    Inventor: Elazar Rabbani
  • Patent number: 11066694
    Abstract: The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: July 20, 2021
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Wayne Patton, Juan Carcamo
  • Publication number: 20210214767
    Abstract: The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 15, 2021
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Wayne Patton, Juan Carcamo, Jack Coleman
  • Publication number: 20210169860
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: November 19, 2020
    Publication date: June 10, 2021
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Sonegan
  • Patent number: 11028121
    Abstract: Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA supramolecular binding molecule noncovalently bound to the oligomer; and (iii) a first reactive group or a first partner of a first binding pair covalently bound to the oligomer. Additionally provided are methods of producing multisignal labeling reagents.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: June 8, 2021
    Assignee: ENZO LIFE SCIENCES, INC.
    Inventors: Jack Coleman, Elazar Rabbani, Jannis Stavrianopoulos, Praveen Pande
  • Publication number: 20210164017
    Abstract: The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.
    Type: Application
    Filed: January 4, 2021
    Publication date: June 3, 2021
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Wayne Patton, Juan Carcamo
  • Publication number: 20210069247
    Abstract: The invention provides cell culture compositions for regulatory T-cells that include particular synthetic peptides. Also provided are methods of treating autoimmune diseases such as age-related macular degeneration and uveitis with regulatory T-cells prepared using said compositions.
    Type: Application
    Filed: September 9, 2020
    Publication date: March 11, 2021
    Applicant: Enzo Biochem, Inc.
    Inventors: Robert Nussenblatt, Baoying LIU, Lai WEI, Elazar RABBANI, James J. DONEGAN
  • Publication number: 20210041456
    Abstract: Provided are immunomodulatory pharmaceutical and non-pharmaceutical compositions that include alpha-synuclein and at least one preselected antigen, such as at least one preselected peptide antigen or immunogen. Also provided are methods for modulating immune activity toward at least one preselected antigen in an at least substantially antigen-specific manner that include administering such a composition to a human patient or to a non-human mammalian subject. Still further provided are enhanced assay methods for quantifying antigen-specific cellular responses, such as cytokine release, to preselected antigens.
    Type: Application
    Filed: August 31, 2020
    Publication date: February 11, 2021
    Applicant: Enzo Biochem, Inc
    Inventors: Ante Tocilj, Jack Coleman, Elazar Rabbani, James J. Donegan
  • Publication number: 20210000766
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: September 22, 2020
    Publication date: January 7, 2021
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan
  • Patent number: 10881643
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: January 5, 2021
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan
  • Publication number: 20200368335
    Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
    Type: Application
    Filed: June 2, 2020
    Publication date: November 26, 2020
    Applicant: Enzo Biochem, Inc.
    Inventors: Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
  • Publication number: 20200360392
    Abstract: The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.
    Type: Application
    Filed: April 21, 2020
    Publication date: November 19, 2020
    Applicant: ENZO BIOCHEM, INC
    Inventors: Elazar Rabbani, Xiaofeng Li, Dakai Liu, Yazhou Zhang, Richard Jin, Riddhi Bhattacharyya, Wei Cheng, James J. Donegan
  • Publication number: 20200332348
    Abstract: a The invention provides nucleic acid hybridization probes having improved detectability that include a plurality of first segments consecutively complementary to a target nucleic acid sequence and, between neighboring first segments, a nucleic acid spacer segment which is not complementary to the target nucleic acid sequence and which may include labeled nucleic acid residues. Also provided by the invention are methods for making the probes, methods for using the probes, and compositions of matter that include the probes hybridized to target nucleic acid molecules.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 22, 2020
    Applicant: ENZO BIOCHEM, INC.
    Inventors: ELAZAR RABBANI, JAMES J. DONEGAN, JACK COLEMAN, MAURIZIO MAURO
  • Publication number: 20200270297
    Abstract: Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA supramolecular binding molecule noncovalently bound to the oligomer; and (iii) a first reactive group or a first partner of a first binding pair covalently bound to the oligomer. Additionally provided are methods of producing multisignal labeling reagents.
    Type: Application
    Filed: March 26, 2020
    Publication date: August 27, 2020
    Applicant: Enzo Life Science, Inc.
    Inventors: Jack Coleman, Elazar Rabbani, Jannis Stavrianopoulos, Praveen Pande
  • Publication number: 20200230113
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: April 8, 2020
    Publication date: July 23, 2020
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan
  • Publication number: 20200222341
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: March 26, 2020
    Publication date: July 16, 2020
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan